Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benefiber ‘Helps Maintain Regularity’ Claim Fails NAD Review; Decision Appealed

This article was originally published in The Tan Sheet

Executive Summary

Novartis Health disagrees with the National Advertising Division decision that the Benefiber express claim “helps maintain regulatory” is not supported by research and will appeal the decision. NAD reviewed the claim made in a challenge by Metamucil fiber supplement marketer P&G.

You may also be interested in...



Neurocet Cliff's Notes Fail NAD Test For 'Stronger Than Morphine' Claim

NAD says direct advertising claims for the Neurocet supplement rely on insufficient or ill-fitted research – including summaries – and marketer National Media Group should discontinue numerous statements challenged by the Council for Responsible Nutrition.

CBD Safety And Hemp Farming Have Equal Space In Rep. Harris’ Concerns

“We ought to deal with this. There are questions on long-term safety and questions on efficacy claims that are just not proven,” says the Maryland Republican. “The biggest threat hanging over, in my mind, the farmers who want to grow hemp, is what if the FDA comes out tomorrow and says, ‘You can't sell any product’? The market collapses,”he said at a CBD policy conference.

House Agriculture Chairman Plants Seeds For FDA's CBD Policy With First Bill

Minnesota Democrat Collin Peterson’s bill, the first targeting FDA’s CBD question, could provide an entire answer or it could set table for discussion in Congress about legislation on establishing an FDA regulation on using CBD, and potentially other hemp-derived substances, in products other than drugs subject to its oversight.

Topics

Related Companies

UsernamePublicRestriction

Register

PS107878

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel